TITLE

Biomaterials in cardiopulmonary bypass

AUTHOR(S)
Courtney, J.M.; Zhao, X.; Qian, H.
PUB. DATE
July 1999
SOURCE
Perfusion;1999, Vol. 14 Issue 4, p263
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the clinical use of biomedical materials in cardiopulmonary bypass procedure. Blood response to biomaterials; Information on biomaterials; Process of polymer synthesis and modification.
ACCESSION #
2115916

 

Related Articles

  • Biomaterial development for cardiopulmonary bypass. Gourlay, T. // Perfusion;Sep2001, Vol. 16 Issue 5, p381 

    Cardiopulmonary bypass (CPB) is dependent on materials foreign to the patient for its successful application. When blood comes into contact with these so-called biomaterials, an inappropriate inflammatory response, which can be life-threatening in some patients, may develop. The reason for this...

  • Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective. Gourlay, T.; Connolly, P. // Perfusion;Jul2003, Vol. 18 Issue 4, p151 

    Cardiopulmonary (CPB) bypass is 50 years old this year, and has undergone considerable change in that time, particularly with regard to developing technology. However, in recent years the routine application of CPB, as the treatment of choice for patients undergoing reparative heart surgery, has...

  • Strategic Leukofiltration in Cardiac Surgery. Gunaydin, S.; McCusker, K.; Vijay, V. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2005, Vol. 3 Issue 4, p323 

    Systemic inflammatory response syndrome (SIRS) with activation of molecular cascades, cell activation, accumulation of interstitial fluid, organ dysfunction and, occasionally, organ failure is still a commonly recognized consequence of cardiac surgery. SIRS leads to costly complications and...

  • The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Rubens, F.D.; Mesana, T. // Perfusion;Jan2004 Supplement 1, Vol. 19, p5 

    The demographic of cardiac surgery patients continues to evolve to include older, sicker candidates, all the while maintaining an expectation of excellent outcomes. These latter results can only be achieved by the parallel advancement and re-examination of the technology of cardiopulmonary...

  • Insulin binding to the cardiopulmonary bypass biomaterials. Urban, Kristyn; Redford, Daniel; Larson, Douglas F. // Perfusion;May2007, Vol. 22 Issue 3, p207 

    Hyperglycemia associated with cardiopulmonary bypass (CPB) is an independent predictor of morbidity and mortality. One suggested cause of hyperglycemia during CPB is a decline of serum insulin concentrations. Since plasma C-proteins are not reduced during CPB - suggesting that pancreatic insulin...

  • The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Sohn, N.; Marcoux, J.; Mycyk, T.; Krahn, J.; Meng, Q. H. // Perfusion;Jul2009, Vol. 24 Issue 4, p231 

    This study was to compare the impact of different biocompatible coated circuits on inflammatory response and oxidative stress induced during cardiopulmonary bypass (CPB). Seventy-eight patients undergoing elective coronary artery bypass grafting (CABG) with CPB were randomly assigned to five...

  • Recent advances in biocompatible surfacemodifying additives for cardiopulmonary bypass. Vijay, Venkataramana; McCusker, Kevin // Perfusion;Mar2003 Supplement, Vol. 18, p41 

    Focuses on technological innovations in biocompatible surface modifying agents (SMA) for cardiopulmonary bypass. Biochemical compatibility parameters for SMA; Clinical compatibility parameters for SMA; Adjuncts and future directions for improved biocompatibility.

  • State of the art in cardiovascular perfusion: now and in the next decade. Merkle, F.; Haupt, B.; El-Essawi, A.; Hetzer, R. // HSR Proceedings in Intensive Care & Cardiovascular Anesthesia;Dec2012, Vol. 4 Issue 4, p211 

    The development and improvement of cardiopulmonary bypass technology is an ongoing process. During the past decade, a number of publications on improvements and best practices have appeared, especially in the areas of biocompatibility, materials sciences, instrumentation, monitoring of...

  • Miniaturized biocompatible cardiopulmonary bypass for the Fontan procedure. Itatani, Keiichi; Miyaji, Kagami; Miyamoto, Takashi; Inoue, Nobuyuki; Tomoyasu, Takahiro; Kohira, Satoshi; Sato, Hajime; Ohara, Kuniyoshi // Surgery Today;Nov2010, Vol. 40 Issue 11, p1040 

    Purpose: Postoperative inflammatory response and perioperative systemic edema are the risks of failed Fontan circulation. We evaluated the efficiency of the miniaturized, poly-2-methoxyethylacrylate (PMEA)-coated cardiopulmonary bypass (CPB) circuit, which we devised in 2003, in the Fontan...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics